Gara Jalqabaatti › Kansarii Hafuu Seli Xiqqaa › Tennessee › Nashville
Qorannoo klinikaalii Kansarii Hafuu Seli Xiqqaa Nashville, TN keessatti
Qorannoo 20 Kansarii Hafuu Seli Xiqqaa f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
Namoota walitti qabaa jiraQorannoo ilaalaa
- Research Site, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Namoota walitti qabaa jiraSadarkaa 3
- SCRI OP (Oncology Partners), Nashville
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute ( Site 7001), Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, PLLC, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 136, Nashville
Qorannoo Kansarii Hafuu Seli Xiqqaa magaalota biroo keessatti
- Houston, TXQorannoo 26
- Arlington, VAQorannoo 23
- New York City, NYQorannoo 22
- Boston, MAQorannoo 21
- Los Angeles, CAQorannoo 20
- Orlando, FLQorannoo 15
- Dallas, TXQorannoo 13
- Cleveland, OHQorannoo 13
- Chicago, ILQorannoo 13
- St. Louis, MOQorannoo 13
- Detroit, MIQorannoo 12
- Washington, DCQorannoo 12
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.